Variability of Hemoglobin Levels After Kidney Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

368 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study es to determine hemoglobin variability in kidney transplant recipients with chronic renal anemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Cardiovascular Risk Following Successful Renal Transplantation

NCT01728012

Renal Transplant

COMPLETED

The Study of Long-term Deterioration of Kidney Transplants.

NCT00217126

Kidney Transplant

COMPLETED

Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients

NCT06025240

Kidney Transplant Renal Transplant Failure Kidney Transplant Rejection +5 more

RECRUITING

Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients

NCT02515643

UNKNOWN

Molecular Biological and Moleculargenetic Monitoring of Therapy After Kidney Transplantation

NCT01515605

Transplantation Infection Kidney Diseases

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary endpoint of the study is hemoglobin level variability. For determination of this variability, the following patterns of hemoglobin level change will be established:

* Target range hemoglobin (TRH): patients with hemoglobin values in the range of 11.0-12.0g/dl throughout the study period.
* Low hemoglobin (LH): patients with levels below 11.0g/dl
* High hemoglobin (HH): patients with levels above 12.0g/dl
* Low-amplitude fluctuation with low hemoglobin (LALH): patients with at least one measurement of hemoglobin levels \<11.0g/dl and at least one measurement in the range of 11.0-12.0g/dl, but without hemoglobin measurements \>12.0g/dl.
* Low-amplitude fluctuation with high hemoglobin (LAHH): patients with at least one measurement of hemoglobin levels \>12.0g/dl and at least one measurement in the range of 11.0-12.0g/dl, but without hemoglobin measurements \<11.0g/dl.
* High-amplitude fluctuation (HAH): patients with at least one measurement of hemoglobin levels \<11.0g/dl and at least one measurement \>12.0g/dl.

Secondary objectives:

* To determine potential factors influencing hemoglobin variability.
* To assess the influence of hemoglobin variability on cardiovascular risk of patients according to the REGICOR function at the end of the study period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

kidney transplantation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged \> or = 18 years.
* Kidney transplant recipients with chronic renal failure stage 3 (glomerular filtration rate: 30-59ml/min/1.73m2), 4 (glomerular filtration rate: 15-29ml/min/1.73m2) or 5 (glomerular filtration rate: \<15ml/min/1.73m2) at the start of the study follow-up period.
* Diagnosis of anemia and drug treatment initiated or changed subsequent to June 29, 2010 (date on which the latest recommendation by European Renal Best Practice on the target range for hemoglobin levels were published)
* Patients capable of giving their informed consent to participate in the study and who agree to participate by signing the informed consent form.